Regulations and Regulatory Advocacy
The Food and Drug Administration announced an import alert on all alcohol-based hand sanitizers from Mexico, noting that 84% of those it analyzed from April through December 2020 did not comply with FDA regulations and more than half contained toxic ingredients at dangerous levels, including鈥
Health and Human Services Secretary Alex Azar directed the department鈥檚 operating divisions and offices to review and revise their procedures related to civil enforcement actions and adjudications 鈥渢o ensure that they promote fairness and transparency.鈥
The AHA provided comments to the Centers for Medicare & Medicaid Services鈥 proposed changes to the hospital and hospital health care complex cost report.
UnitedHealthcare has suspended through the end of this month certain prior authorization requirements for in-network hospitals and skilled nursing facilities in its Medicare Advantage, Medicaid, individual and group health plans.
At A Glance
Health plans often inappropriately delay or decline coverage for medically necessary care. This can undermine the quality of care that is provided, strain the provider/patient relationship, result in bad debt for providers and unexpected bills for patients, and increase the burden on鈥
AHA comments on the Centers for Medicare & Medicaid Services鈥 proposed changes to the hospital and hospital health care complex cost report.
Under a final rule, the Department of Health and Human Services must periodically assess each regulation to determine whether it has a significant economic impact on a substantial number of small entities, and if so review the regulation to determine whether to retain, modify or eliminate it.
AHA letter urging HHS to exercise enforcement discretion with respect to the hospital price transparency rule.
AHA comments on CMS鈥 proposed rule on prior authorization.
The AHA submitted comments to a Centers for Medicare & Medicaid Services request for information on regulatory relief to support economic recovery. Specifically, AHA urged the agency to take additional action to remove certain regulatory barriers standing in the way of efficiency and innovation鈥